N/A N=300 HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
Phase 2 N=192 H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
Influenza
Primary: Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…
N/A N=799 Positive Health Check Evaluation Trial
Human Immunodeficiency Virus (HIV) Positive
Primary: Number of Participants With Viral Load Suppression — 210; 213 Participants — p=0.220
N/A N=41 Longitudinal Study of Dental Implant Therapy in HIV Positive Patients
Dental Implant
Primary: Number of Implants Functioning in HIV Positive Subjects Compared to HIV Negative Subjects — 28; 25 implants
Phase 4 N=1,771 Antiretroviral Therapy for Advanced HIV Disease in South Africa
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
Phase 1 N=46 PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects
Depression · HIV Infections · HIV-Associated Cognitive Motor Complex
Primary: Influx Constant (Ki) for 18F-FDOPA PET. — 0.01415; 0.01409; 0.01588; 0.01592 min-1
N/A N=106 Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
Risk Behavior · Medication Adherence · HIV
Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants
N/A N=37 Cardiovascular Prevention for Persons With HIV
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus
Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants
N/A N=216 Treatment Advocacy Intervention for HIV-Positive African Americans
HIV
Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005
N/A N=219 HIV-Tb Confections Among HIV Patients
HIV
Primary: Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center. — 48 participants
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
Phase 4 N=371 Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
HIV Infection · Hepatitis B
Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440
Phase 2 N=240 Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
Tuberculosis
Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 1; 0; 1; 0 Participants
Phase 2 N=7 Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
N/A N=249 Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission
HIV Infections
Primary: Proportion of Patients With Newly Diagnosed HIV Infection at Care Seeking — 50; 13; 37; 2 Participants
N/A N=43 LinkPositively: A Technology-Delivered Peer Navigation and Social Networking Intervention to Improve HIV Care
HIV/AIDS
Primary: Number of HIV Care Visits — 1.00; 3.00 HIV Care Visits
N/A N=282,368 Kaiser Permanente HIV Cohort Study
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
N/A N=114 Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
N/A N=12 Psychosocial Intervention for Older HIV+ Adults With HAND
HIV/AIDS · Aging · Mild Cognitive Impairment
Primary: Feasibility - Session Attendance — 5; 5 Participants
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
Phase 2 N=150 Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infections, Papillomavirus
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms — 46; 18; 19; 2 Participants
N/A N=9,572 HIV Screening in the Emergency Department Setting
HIV Infections
Primary: Percentage of Tested Participants Newly Diagnosed as HIV Infected — 6; 3 percentage of tested that are positive
Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Phase 3 N=1,456 Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women
Human Immunodeficiency Virus
Primary: The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women — 52; 19; 2 Participants
Phase 2 N=24 Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy
HIV
Primary: Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels — 0; 0; -0.03; -0.08 Log10 copies/ml plasma
N/A N=506 RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers
Tobacco Use Disorder · HIV
Primary: Number of Participants Achieving 7-day Point Prevalence Abstinence From Tobacco Use — 38; 22; 217; 229 Participants